Floatz logo

Hycamtin

First-Line

Danish Oncological Lung Cancer GroupPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the First-Line cohort.

Asset / SponsorPhaseRating
Carboplatin
Danish Oncological Lung Cancer Group
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Danish Oncological Lung Cancer Group
Phase 3B
ETOPOSIDE
Danish Oncological Lung Cancer Group
Phase 3B
Irinotecan
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC
Tislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC

View all 9 →

Same molecule, other indications

Hycamtin is also rated in:

primary peritoneal carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
non-small cell lung carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →